Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-Arm, Multicenter, Open-Label Clinical Study to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel Injection as First-Line Therapy of High-Risk Large B-Cell Lymphoma

NCT06935136 is registered in ClinicalTrials.gov with Ruijin Hospital as lead sponsor.

NCT NCT06935136
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06935136 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-Arm, Multicenter, Open-Label Clinical Study to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel Injection as First-Line Therapy of High-Risk Large B-Cell Lymphoma
Lead sponsor
Ruijin Hospital
Phase
Not applicable
Overall status
Not yet recruiting
Start date
April 30, 2025
Completion date
April 9, 2028
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

car-t cell therapy, high-risk large b-cell lymphoma (lbcl)